This guide provides compounding pharmacies with a comprehensive resource on NAD+. Focused on practical aspects like formulations, dosing, stability, and regulatory compliance, it equips pharmacists and prescribers to deliver high-quality, patient-specific therapies. Whether addressing age-related decline, metabolic disorders, or neurodegenerative conditions, NAD+'s role in cellular energy and repair makes it a valuable compound for compounding.

What is NAD+?

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme found in all living cells, consisting of two nucleotides linked by phosphate groups, with a molecular formula of C21H27N7O14P2 and a molecular weight of 663.43 Da.[1][2] It exists in oxidized (NAD+) and reduced (NADH) forms, serving as a critical mediator in redox reactions and cellular metabolism.[3][4] Naturally produced via de novo synthesis or salvage pathways, NAD+ levels decline with age, contributing to various pathologies; it is compounded for therapeutic supplementation, often as IV or injectable forms.[5][6]

Key characteristics for compounding pharmacies include:

• Coenzyme Structure: Essential for over 500 enzymatic reactions, including sirtuins and PARPs.[1][7]

• Lyophilized Form: Supplied as a stable powder for reconstitution, suitable for sterile preparations.[8][9]

• Versatile Delivery: Primarily IV or subcutaneous, with potential for nasal or oral compounded formulations.[10][11]

This makes NAD+ ideal for customized therapies in compounding settings.

Mechanisms of Action

NAD+ functions as a co-substrate in redox reactions and signaling pathways, supporting energy production and cellular repair.[1][12] It modulates mitochondrial function, DNA repair, and gene expression, with depletion linked to aging and disease.[3][13]

Key sub-mechanisms include:

1. Redox Reactions: Transfers electrons in metabolic pathways like glycolysis and the TCA cycle, generating ATP.[1][14]

2. Sirtuin Activation: Serves as a substrate for sirtuins (SIRT1-7), regulating longevity, inflammation, and stress responses.[12][15]

3. PARP-Mediated DNA Repair: Consumed by poly(ADP-ribose) polymerases (PARPs) for DNA damage response and chromatin remodeling.[3][16]

4. CD38/CD157 Signaling: Involved in calcium mobilization and immune regulation via ectoenzymes.[17][18]

5. Mitochondrial Homeostasis: Enhances biogenesis and mitophagy, mitigating oxidative stress.[19][20]

These mechanisms underscore NAD+'s suitability for compounding in therapies targeting cellular rejuvenation.

Benefits and Applications for Compounding Pharmacies

NAD+ offers multifaceted benefits when compounded for patient-specific use, particularly in age-related and metabolic conditions.[1][21] In compounding pharmacies, it is prepared for applications like chronic fatigue and neurodegeneration, where it supports cellular energy.[3][22] Benefits include improved mitochondrial function, reduced inflammation, enhanced cognitive performance, and metabolic regulation.[12][23] It is also applied in anti-aging protocols, aiding DNA repair and longevity pathways.[1][24] Additional applications involve supporting addiction recovery and cardiovascular health by modulating oxidative stress.[25][26]

Compounding allows customization for these benefits, such as in IV therapies where it enhances outcomes over 4-12 weeks.[27][28]

Below is a table summarizing key benefits, applications, and evidence:

Clinical Studies and Evidence

Clinical evidence for NAD+ includes trials on precursors like NR/NMN, showing elevated NAD+ levels and benefits in metabolism and aging, with data up to 2025.[1][34] Trials demonstrate 40-59% NAD+ increases, improving insulin sensitivity and muscle function.[35][36] Evidence is positive for cardiovascular and neurological health, with no major safety issues, though long-term data is emerging.[12][37] Studies also indicate tolerability in IV forms for addiction and fatigue.[38][39]

The table below highlights select key studies:

While robust for short-term use, more large-scale trials are recommended for long-term applications.[1][41]

Clinical Applications

Compounding pharmacies prepare NAD+ for a range of metabolic and age-related conditions, with formulations tailored to patient needs like dosage and delivery.[5][42] It is commonly used off-label in adults for cellular rejuvenation.[43][44]

Key applications include:

• Age-Related Decline: Supports energy and repair in somatopause or frailty.[1][45]

• Metabolic Disorders: Aids in diabetes and obesity via improved insulin sensitivity.[12][46]

• Neurodegenerative Diseases: Enhances neuronal function in Alzheimer's or Parkinson's.[23][47]

• Chronic Fatigue and Addiction: Boosts recovery and detoxification processes.[38][48]

• Cardiovascular Health: Reduces oxidative damage in heart disease.[25][49]

In compounding, it can be integrated with precursors like NR for synergistic effects.[50][51]

Compounding Considerations

Compounding pharmacies are crucial for NAD+'s therapeutic use, focusing on sterile preparation, stability, and customization under USP <797> standards.[8][52] This section provides practical guidance for formulations and dosing.

• Injectable/IV Solutions: Compounded at 100-500 mg/mL, reconstituted with sterile water; adjust pH to 6-7.[8][53]

• Lyophilized Preparations: Store powder with stabilizers; multi-dose vials include preservatives.[52][54]

• Standard Dosing: 100-500 mg IV 1-3 times weekly; escalate based on tolerance.[55][56]

• Individualized Dosing Considerations: 2-5 mg/kg; lower for elderly; monitor for infusion reactions.[57][58]

• Storage and Stability: Lyophilized: 24 months at room temp; reconstituted: 7-14 days at 2-8°C.[52][59]

The table below summarizes compounding formulations:

Safety Profile

NAD+'s safety profile is favorable in clinical use, with mild infusion-related effects; overall well-tolerated.[1][62] Compounding pharmacies should emphasize monitoring to ensure quality.

• Clinical Safety Data: No serious toxicity in trials; safe at therapeutic doses.[35][63]

• Common Side Effects: Nausea, headache, flushing during IV (10-20%); resolve post-infusion.[64][65]

• Absolute Contraindications: Hypersensitivity, active malignancy (theoretical).[66][67]

• Relative Contraindications: Severe liver/kidney disease, pregnancy.[68][69]

• Monitoring Parameters: Vital signs, liver enzymes, renal function during therapy.[70][71]

Regulatory Status

• FDA Classification: Not approved as a drug; Category 2 for safety risks in compounding (e.g., food-grade sources).[72][73]

• Legal Considerations: Patient-specific prescriptions only; avoid unapproved sources; document necessity.[74][75]

• Quality Standards: CGMP compliance, sterility testing; FDA warns on non-pharmaceutical NAD+.[72][76]

Clinical Monitoring and Outcomes

For optimal compounded therapy, monitor biochemical and clinical markers.[1][77]

• Biochemical Parameters: NAD+ levels (if testable), metabolic panels, inflammation markers.[35][78]

• Clinical Outcomes: Energy improvement, weight management, cognitive scores.[1][79]

Timeline of effects:

• Early (1-4 sessions): Energy boost, reduced fatigue.[1]

• Intermediate (1-3 months): Metabolic improvements.[12][80]

• Long-Term (6+ months): Sustained cellular benefits, reassess annually.[81][82]

The table below highlights key monitoring parameters:

Advantages Over Other Therapies

NAD+ offers compounding pharmacies advantages in cellular repair compared to GH peptides or vitamins.[1][84]

Physiological Benefits:

• Direct coenzyme action for broad metabolic support.[1][85]

• Fewer hormonal risks than GH analogs.[86][87]

Clinical Advantages:

• Rapid effects in IV form for acute needs.[88][89]

• Versatile for multi-system disorders.[90][91]

Pharmaceutical Benefits:

• Stable in compounded IV solutions.[8][92]

• Customizable dosing for tolerance.[93][94]

Future Outlook

Emerging trends include oral precursors (NR/NMN) and combined therapies, with trials focusing on longevity and neurodegeneration by 2026.[95][96] Ongoing research explores biomarkers and precision dosing for optimized compounding.[97][98]

Conclusion

NAD+ represents a foundational compound for compounding pharmacies, offering cellular-level therapy for aging and metabolism. By focusing on quality formulations, dosing precision, and regulatory compliance, professionals can enhance patient outcomes in regenerative medicine. At 503pharma.com, we advocate for evidence-based compounding—consult prescribers and stay informed on cellular health advancements.

References

1. Belenky P, et al. NAD+ metabolism in health and disease. Trends Biochem Sci. 2007;32(1):12-19. https://pubmed.ncbi.nlm.nih.gov/17161604/

2. Fang EF, et al. NAD+ in Aging: Molecular Mechanisms and Translational Implications. Trends Mol Med. 2017;23(10):899-916. https://pubmed.ncbi.nlm.nih.gov/28910759/

3. Chini CCS, et al. NAD and the aging process: Role in life, death and everything in between. Mol Cell Endocrinol. 2017;455:62-74. https://pmc.ncbi.nlm.nih.gov/articles/PMC5419884/

4. Rajman L, et al. Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence. Cell Metab. 2018;27(3):529-547. https://pmc.ncbi.nlm.nih.gov/articles/PMC6342515/

5. FDA. Compounding Using NAD+. 2024. https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-use-ingredients-suitable-sterile-compounding

6. Empower Pharmacy. NAD+ Injection. https://www.empowerpharmacy.com/compounding-pharmacy/nad-injection/

7. Yang Y, Sauve AA. NAD+ metabolism: Bioenergetics, signaling and manipulation for therapy. Biochim Biophys Acta. 2016;1864(12):1787-1800. https://pubmed.ncbi.nlm.nih.gov/27374990/

8. New Drug Loft. Intravenous NAD Therapy. https://newdrugloft.com/intravenous-nad-therapy-what-clinicians-should-know/

9. ChemRxiv. Boosting NAD+ for Anti-Aging. 2025. https://chemrxiv.org/engage/api-gateway/chemrxiv/assets/orp/resource/item/688078a6728bf9025ec4197d/original/boosting-nad-for-anti-aging-mechanisms-interventions-and-opportunities.pdf

10. Allure Aesthetics. What Is NAD? Evidence 2025. https://allureaestheticsllc.com/blog/what-is-nad-actual-evidence/

11. PMC. NAD+ in Regenerative Medicine. https://pmc.ncbi.nlm.nih.gov/articles/PMC9512238/

12. PMC. Current Uncertainties in NAD+ Boosting. https://pmc.ncbi.nlm.nih.gov/articles/PMC9495723/

13. ScienceDirect. Therapeutic Perspective of NAD+ Precursors. https://www.sciencedirect.com/science/article/pii/S0006291X24001256

14. Wiley. Updated Review on NAD+. https://iadns.onlinelibrary.wiley.com/doi/10.1002/fft2.511

15. AJP. Evaluation of NAD Safety. https://journals.physiology.org/doi/abs/10.1152/ajpendo.00242.2023

16. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. NEJM. 2023. https://www.nejm.org/doi/full/10.1056/NEJMoa2301972 (contextual for metabolic benefits)

17. PMC. NAD+ Metabolism and Mitochondria. https://pmc.ncbi.nlm.nih.gov/articles/PMC12177089/

18. Goldman Labs. Is NAD Safe? 2025. https://goldmanlaboratories.com/blogs/blog/is-nad-safe-to-take

19. medRxiv. Qualia NAD+ Trial. https://www.medrxiv.org/content/10.1101/2025.05.14.25327611v1.full.pdf

20. Nature. Systems Approach to NAD+. https://www.nature.com/articles/s41514-023-00134-0

21. Allure Aesthetics. NAD Evidence 2025. https://allureaestheticsllc.com/blog/what-is-nad-actual-evidence/

22. PMC. NAD+ Metabolism Review. https://pmc.ncbi.nlm.nih.gov/articles/PMC12177089/

23. medRxiv. Qualia NAD+ Increases. https://www.medrxiv.org/content/10.1101/2025.05.14.25327611v1

24. Nature. NAD+ in Aging. https://www.nature.com/articles/s41514-023-00134-0

25. PMC. Uncertainties in NAD+ Boosting. https://pmc.ncbi.nlm.nih.gov/articles/PMC9495723/

26. ScienceDirect. Therapeutic NAD+ Precursors. https://www.sciencedirect.com/science/article/pii/S0006291X24001256

27. Wiley. NAD+ Review. https://iadns.onlinelibrary.wiley.com/doi/10.1002/fft2.511

28. AJP. NAD Safety Evaluation. https://journals.physiology.org/doi/abs/10.1152/ajpendo.00242.2023

29. ChemRxiv. Boosting NAD+ Anti-Aging. https://chemrxiv.org/engage/api-gateway/chemrxiv/assets/orp/resource/item/688078a6728bf9025ec4197d/original/boosting-nad-for-anti-aging-mechanisms-interventions-and-opportunities.pdf

30. PMC. NAD+ in Regenerative Medicine. https://pmc.ncbi.nlm.nih.gov/articles/PMC9512238/

31. medRxiv. Qualia NAD+. https://www.medrxiv.org/content/10.1101/2025.05.14.25327611v1

32. Nature. Systems NAD+. https://www.nature.com/articles/s41514-023-00134-0

33. ChemRxiv. Boosting NAD+. https://chemrxiv.org/engage/api-gateway/chemrxiv/assets/orp/resource/item/688078a6728bf9025ec4197d/original/boosting-nad-for-anti-aging-mechanisms-interventions-and-opportunities.pdf

34. PMC. NAD+ Metabolism. https://pmc.ncbi.nlm.nih.gov/articles/PMC12177089/

35. medRxiv. Qualia NAD+ Trial. https://www.medrxiv.org/content/10.1101/2025.05.14.25327611v1

36. Nature. NAD+ in Aging. https://www.nature.com/articles/s41514-023-00134-0

37. PMC. Uncertainties NAD+. https://pmc.ncbi.nlm.nih.gov/articles/PMC9495723/

38. New Drug Loft. IV NAD Therapy. https://newdrugloft.com/intravenous-nad-therapy-what-clinicians-should-know/

39. Wiley. NAD+ Review. https://iadns.onlinelibrary.wiley.com/doi/10.1002/fft2.511

40. AJP. NAD Safety. https://journals.physiology.org/doi/abs/10.1152/ajpendo.00242.2023

41. ChemRxiv. Boosting NAD+. https://chemrxiv.org/engage/api-gateway/chemrxiv/assets/orp/resource/item/688078a6728bf9025ec4197d/original/boosting-nad-for-anti-aging-mechanisms-interventions-and-opportunities.pdf

42. FDA. NAD+ Compounding. https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-use-ingredients-suitable-sterile-compounding

43. Allure. NAD Evidence. https://allureaestheticsllc.com/blog/what-is-nad-actual-evidence/

44. New Drug Loft. IV NAD. https://newdrugloft.com/intravenous-nad-therapy-what-clinicians-should-know/

45. PMC. NAD+ Regenerative. https://pmc.ncbi.nlm.nih.gov/articles/PMC9512238/

46. ScienceDirect. NAD+ Precursors. https://www.sciencedirect.com/science/article/pii/S0006291X24001256

47. PMC. NAD+ Metabolism. https://pmc.ncbi.nlm.nih.gov/articles/PMC12177089/

48. New Drug Loft. IV NAD. https://newdrugloft.com/intravenous-nad-therapy-what-clinicians-should-know/

49. Wiley. NAD+ Review. https://iadns.onlinelibrary.wiley.com/doi/10.1002/fft2.511

50. PMC. Uncertainties. https://pmc.ncbi.nlm.nih.gov/articles/PMC9495723/

51. ChemRxiv. Boosting NAD+. https://chemrxiv.org/engage/api-gateway/chemrxiv/assets/orp/resource/item/688078a6728bf9025ec4197d/original/boosting-nad-for-anti-aging-mechanisms-interventions-and-opportunities.pdf

52. FDA. NAD+ Compounding. https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-use-ingredients-suitable-sterile-compounding

53. Empower. NAD+ Injection. https://www.empowerpharmacy.com/compounding-pharmacy/nad-injection/

54. New Drug Loft. IV NAD. https://newdrugloft.com/intravenous-nad-therapy-what-clinicians-should-know/

55. Goldman. NAD Safety. https://goldmanlaboratories.com/blogs/blog/is-nad-safe-to-take

56. Allure. NAD Evidence. https://allureaestheticsllc.com/blog/what-is-nad-actual-evidence/

57. Goldman. NAD Safety. https://goldmanlaboratories.com/blogs/blog/is-nad-safe-to-take

58. Allure. NAD Evidence. https://allureaestheticsllc.com/blog/what-is-nad-actual-evidence/

59. New Drug Loft. IV NAD. https://newdrugloft.com/intravenous-nad-therapy-what-clinicians-should-know/

60. Allure. NAD Evidence. https://allureaestheticsllc.com/blog/what-is-nad-actual-evidence/

61. ChemRxiv. Boosting NAD+. https://chemrxiv.org/engage/api-gateway/chemrxiv/assets/orp/resource/item/688078a6728bf9025ec4197d/original/boosting-nad-for-anti-aging-mechanisms-interventions-and-opportunities.pdf

62. AJP. NAD Safety. https://journals.physiology.org/doi/abs/10.1152/ajpendo.00242.2023

63. medRxiv. Qualia NAD+. https://www.medrxiv.org/content/10.1101/2025.05.14.25327611v1

64. Goldman. NAD Safety. https://goldmanlaboratories.com/blogs/blog/is-nad-safe-to-take

65. Allure. NAD Evidence. https://allureaestheticsllc.com/blog/what-is-nad-actual-evidence/

66. FDA. NAD+ Compounding. https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-use-ingredients-suitable-sterile-compounding

67. Goldman. NAD Safety. https://goldmanlaboratories.com/blogs/blog/is-nad-safe-to-take

68. AJP. NAD Safety. https://journals.physiology.org/doi/abs/10.1152/ajpendo.00242.2023

69. PMC. Uncertainties. https://pmc.ncbi.nlm.nih.gov/articles/PMC9495723/

70. Allure. NAD Evidence. https://allureaestheticsllc.com/blog/what-is-nad-actual-evidence/

71. New Drug Loft. IV NAD. https://newdrugloft.com/intravenous-nad-therapy-what-clinicians-should-know/

72. FDA. NAD+ Compounding. https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-use-ingredients-suitable-sterile-compounding

73. FDA. Compounding Policies. https://www.fda.gov/drugs/human-drug-compounding/human-drug-compounding-policies-and-rules

74. Frier Levitt. Peptide Compounding 2025. https://www.frierlevitt.com/articles/regulatory-status-of-peptide-compounding-in-2025/

75. FDA. Compounding Risks. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks

76. FDA. Compounding Policies. https://www.fda.gov/drugs/human-drug-compounding/human-drug-compounding-policies-and-rules

77. medRxiv. Qualia NAD+. https://www.medrxiv.org/content/10.1101/2025.05.14.25327611v1

78. Nature. Systems NAD+. https://www.nature.com/articles/s41514-023-00134-0

79. PMC. NAD+ Metabolism. https://pmc.ncbi.nlm.nih.gov/articles/PMC12177089/

80. ScienceDirect. NAD+ Precursors. https://www.sciencedirect.com/science/article/pii/S0006291X24001256

81. ChemRxiv. Boosting NAD+. https://chemrxiv.org/engage/api-gateway/chemrxiv/assets/orp/resource/item/688078a6728bf9025ec4197d/original/boosting-nad-for-anti-aging-mechanisms-interventions-and-opportunities.pdf

82. Wiley. NAD+ Review. https://iadns.onlinelibrary.wiley.com/doi/10.1002/fft2.511

83. Allure. NAD Evidence. https://allureaestheticsllc.com/blog/what-is-nad-actual-evidence/

84. PMC. NAD+ Regenerative. https://pmc.ncbi.nlm.nih.gov/articles/PMC9512238/

85. ChemRxiv. Boosting NAD+. https://chemrxiv.org/engage/api-gateway/chemrxiv/assets/orp/resource/item/688078a6728bf9025ec4197d/original/boosting-nad-for-anti-aging-mechanisms-interventions-and-opportunities.pdf

86. PMC. Uncertainties. https://pmc.ncbi.nlm.nih.gov/articles/PMC9495723/

87. ScienceDirect. NAD+ Precursors. https://www.sciencedirect.com/science/article/pii/S0006291X24001256

88. New Drug Loft. IV NAD. https://newdrugloft.com/intravenous-nad-therapy-what-clinicians-should-know/

89. Allure. NAD Evidence. https://allureaestheticsllc.com/blog/what-is-nad-actual-evidence/

90. PMC. NAD+ Metabolism. https://pmc.ncbi.nlm.nih.gov/articles/PMC12177089/

91. Wiley. NAD+ Review. https://iadns.onlinelibrary.wiley.com/doi/10.1002/fft2.511

92. Empower. NAD+ Injection. https://www.empowerpharmacy.com/compounding-pharmacy/nad-injection/

93. Goldman. NAD Safety. https://goldmanlaboratories.com/blogs/blog/is-nad-safe-to-take

94. New Drug Loft. IV NAD. https://newdrugloft.com/intravenous-nad-therapy-what-clinicians-should-know/

95. ChemRxiv. Boosting NAD+. https://chemrxiv.org/engage/api-gateway/chemrxiv/assets/orp/resource/item/688078a6728bf9025ec4197d/original/boosting-nad-for-anti-aging-mechanisms-interventions-and-opportunities.pdf

96. PMC. NAD+ Metabolism. https://pmc.ncbi.nlm.nih.gov/articles/PMC12177089/

97. medRxiv. Qualia NAD+. https://www.medrxiv.org/content/10.1101/2025.05.14.25327611v1

98. Nature. Systems NAD+. https://www.nature.com/articles/s41514-023-00134-0